← Back to headlines
ImmunityBio's ANKTIVA Value Highlighted Over TAR-200 in Health Economic Analysis
A health economic analysis has underscored the value of ImmunityBio's (IBRX) ANKTIVA, positioning it favorably against TAR-200. This comparison suggests ANKTIVA's potential benefits in the therapeutic landscape.
29 May, 06:42 — 29 May, 06:42
Sources
Showing 1 of 1 sources
